New Studies Show How Using GE Healthcare’s MultiOmyx™ In Hodgkin Lymphoma And Breast Cancer Cases May Improve Disease Assessment
GE Healthcare today announced results from two studies that show how
using the MultiOmyx
™ Hodgkin Lymphoma (HL) Profile and an
investigational profile for breast cancer may improve assessment of the
GE Healthcare today announced results from two studies that show how using the MultiOmyx ™ Hodgkin Lymphoma (HL) Profile and an investigational profile for breast cancer may improve assessment of the two diseases in subsets of patients. “These data show how using MultiOmyx can empower pathologists and oncologists to gain a much deeper understanding of what can be seen in a tumor, on a slide, region of interest or at a cellular level in a variety of cancers,” said Christine Kuslich, PhD, Chief Scientific Officer, In Vitro Diagnostics, GE Healthcare Life Sciences. “The ability to multiplex and visualize the contextual relationship between key proteins in the same cells from a single piece of tissue will help investigators answer questions they previously did not have the tools for. We can now investigate complex protein networks without disrupting their cellular relationship to the surrounding tissue.” MultiOmyx is a ground-breaking pathology platform from Clarient Diagnostic Services, a GE Healthcare Company, which uses proprietary methodology to assess multiple proteins in a tissue section at a single-cell level, while preserving tissue context. In addition to the global service offering for clinical suspected Hodgkin lymphoma cases, the MulitOmyx services are also available to pharmaceutical, biotechnology and academic research organizations for research purposes through Clarient’s newly-opened MultiOmyx service laboratory. “Traditional pathology uses multiple slices from paraffin-fixed tumor samples and examines them slide by slide, which is less efficient and effective,” said Kenneth Bloom, MD, Chief Medical Officer, Clarient Diagnostic Services, Inc. “Using a single slide may save time overall, uses significantly less tissue and may provide a more consistent result. Since different parts of a tumor sample can act differently and because less tissue is required, pathologists can perform accurate and broad tumor analyses, while eliminating today’s need to prioritize tests due to limited tissue availability.” The studies will be presented at the 55 th Annual Meeting of the American Society of Hematology (ASH) and the 2013 San Antonio Breast Cancer Symposium (SABCS). About the Studies The study presented at ASH assessed CD30-positive cells with eight additional antibodies on the same cells of interest from formalin-fixed, paraffin-embedded tissue as an aid to diagnose Hodgkin lymphoma in a series of 23 cases. In addition, 56 unique cases were studied for diagnostic concordance. The study compared historical diagnosis using immunohistochemistry to the MultiOmyx assessment, studying blinded cases of classical Hodgkin lymphoma and other differential diagnosis entities and found 54 of the 56 cases showed complete concordance with the disparate cases favoring the MultiOmyx supported assessment.. Results from the study found that the MultiOmyx single slide assay has similar staining characteristics and is at least equivalent to standard immunohistochemical stains, allowing for better correlation of results between stains in a given case, particularly in cases with rare Hodgkin cells, since it allows direct comparison of stains within the same field of view and on the same cells. Separately, results from an exploratory study to be presented at SABCS evaluate 25 known biomarkers on a cohort of more than 800 breast cancer cases assembled onto three tissue arrays to assess the ability of a MultiOmyx profile to screen for prognostic indicators of breast cancer. These studies add to the growing body of evidence supporting the efficacy of the MultiOmyx platform, including posters presented earlier this year at the annual meetings of the Association of Molecular Pathology (AMP), United States and Canadian Academy of Pathology (USCAP) and American Society of Clinical Oncology (ASCO), as well as the 9 th International Society of Hodgkin Lymphoma and 15 th World Congress on Lung Cancer. About The Hodgkin Lymphoma Profile by MultiOmyx The Hodgkin Lymphoma Profile by MultiOmyx has been commercially available since July 2013 as a consult service through Clarient Diagnostic Services, Inc. and helps to assess nine unique antibodies (CD30, CD15, CD20, CD45, PAX5, OCT2, BOB1, CD3, and CD79A) on a single formalin fixed paraffin embedded tissue section to aid in differential diagnosis of Classical HL. In clinical validation, this single slide assay demonstrated high levels of accuracy, diagnostic reproducibility and repeatability, and high sensitivity of all immunofluorescent stains in comparison to traditional immunohistochemistry performed on the same samples. The correlation study identified unique cases where MultiOmyx demonstrated improved performance.